Key facts
- This page summarizes Richard E. Lowenthal's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 Apr 2024, 19:22.
Richard E. Lowenthal - 19 Apr 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)
- Reporting relationship
- PRESIDENT AND CEO, Director, 10%+ Owner
- Issuer ticker
- SPRY
- Reported as of
- 19 Apr 2024
- Net transaction value
- +$199,999
- SEC form
- 4
- Accepted by SEC
- 22 Apr 2024, 19:22:25 UTC
- Prior SEC filing
- 17 Apr 2024
- Next SEC filing
- 24 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathleen Scott, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard E. Lowenthal filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 22 Apr 2024.
Change
- Previous filing in this sequence was filed on 17 Apr 2024.
- Current net transaction value: +$199,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRY
transaction
Common Stock
Options Exercise
- Transaction value
- $99,999
- Shares
- +119,047
- Change %
- +2.9%
- Price
- $0.8400*
- Shares after
- 4,245,869
- Date
- 19 Apr 2024
- Ownership
- Direct
SPRY
transaction
Common Stock
Options Exercise
- Transaction value
- $99,999
- Shares
- +69,444
- Change %
- +1.6%
- Price
- $1.44
- Shares after
- 4,315,313
- Date
- 19 Apr 2024
- Ownership
- Direct
SPRY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,276,854
- Date
- 19 Apr 2024
- Ownership
- By Spouse
SPRY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,646,494
- Date
- 19 Apr 2024
- Ownership
- By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020
- Footnotes
- F1
SPRY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,848,499
- Date
- 19 Apr 2024
- Ownership
- By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006
- Footnotes
- F2
SPRY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,647,447
- Date
- 19 Apr 2024
- Ownership
- By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRY
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -119,047
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 117,333
- Date
- 19 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 119,047
- Exercise price
- $0.8400
- Footnotes
- F4
SPRY
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -69,444
- Change %
- -29%
- Price
- $0.000000
- Shares after
- 166,936
- Date
- 19 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,444
- Exercise price
- $1.44
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Reporting Person is trustee of the trust.
Footnote F2
The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
Footnote F3
The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Footnote F4
25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.